VZL 2008, 77(4):145-148

Continuous 24-Hours Monitoring of Electrocardiogram during Anthracycline-Based Therapy

Martin Jakl ORCID...1,2, Jan M. Horáček ORCID...3,4, Radek Pudil2, Ladislav Jebavý3,4
1 Univerzita obrany, Fakulta vojenského zdravotnictví, Hradec Králové
2 I. interní klinika Fakultní nemocnice a Lékařská fakulty UK v Hradci Králové
3 Univerzita obrany, katedra válečného vnitřního lékařství Fakulty vojenského zdravotnictví, Hradec Králové
4 Oddělení klinické hematologie II. interní kliniky Fakultní nemocnice a Lékařské fakulty UK v Hradci Králové

Akutní kardiotoxicita je jedním z nežádoucích účinků antracyklinových cytostatik. Práce se zaměřuje na posouzení vhodnosti kontinuální 24hodinové monitorace elektrokardiogramu u pacientů léčených antracykliny. Do studie bylo zařazeno 19 pacientů s akutní leukémií, kteří byli léčeni chemoterapií obsahující antracyklinový preparát. U každého pacienta byly pořízeny dva standardní 24hodinové holterovské záznamy EKG, první před prvním podáním antracyklinu a druhý v průběhu a po podání antracyklinu. V průběhu podávání a po podání antracyklinového preparátu došlo k poklesu tepové frekvence a prodloužení intervalů PQ, QRS a QTc. Nedošlo ke statisticky významnému nárůstu četnosti ani závažnosti arytmií. Četnost i závažnost arytmií po podání antracyklinů však vykazovala středně silnou až silnou závislost na výskytu arytmií před léčbou. Ve sledovaném souboru se dále vyskytlo 6 (31,6 %) pacientů s komorovými extrasystolami typu R na T asociovanými s prodlouženým intervalem QTc. U těchto pacientů lze předpokládat největší prospěch z monitorování elektrokardiogramu v průběhu léčby antracyklinovými preparáty.

Keywords: Antracykliny; Akutní kardiotoxicita; Holterovské monitorování; Akutní leukémie

The acute cardiac toxicity of anthracyclines is one of possible side effects of anthracyclines. The study is focused on applicability of the continuous 24-hours monitoring of electrocardiogram in patients treated with anthracyclines. There were 19 patients, who had a newly diagnosed acute leukemia and were treated with chemotherapy containing anthracyclines, participating in the study. Two standard 24-hours Holter ECG records were made in each patient, the first before the onset of administration of anthracyclines and the other during and after the administration of anthracyclines. During and after the administration of anthracyclines the length of the PQ, QRS and QTc interval increased, whereas the heart rate decreased. The count of the supraventricular as well as ventricular premature beats didn't increase. The occurrence as well as the severity of arrhythmias showed mesoscale or strong dependence on the occurrence and the severity of arrhythmias before the treatment. There were 6 (31.6 %) patients with R on T type ventricular premature beats associated with prolonged QTc interval in our group. In these patients, the biggest benefit from monitoring of the electrocardiogram during therapy containing anthracyclines may be suspected.

Keywords: Anthracyclines; Acute cardiac toxicity; Holter monitoring; Acute leukemia

Received: November 20, 2007; Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jakl, M., Horáček, J.M., Pudil, R., & Jebavý, L. (2008). Continuous 24-Hours Monitoring of Electrocardiogram during Anthracycline-Based Therapy. Vojenské Zdravotnické Listy77(4), 145-148
Download citation

References

  1. O'BRYAN, RM., et al. Phase II evaluation of adriamycin in human neoplasm. Cancer, 1973, vol. 32, p. 1-8. Go to original source...
  2. NOUSIAINEN, T., et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodkin's lymphoma. J. Intern. Med., 1999, vol. 245, p. 359-364. Go to original source... Go to PubMed...
  3. PRAGA, C., et al. Adriamycin cardiotoxicity, a survey of 1273 patients. Cancer Treat. Rep., 1979, vol. 63, p. 827-834.
  4. VON HOFF, DD. - ROZENCWEIG, M. - PICCART, M. The cardiotoxicity of anticancer agents. Semin. Oncol., 1982, vol. 9, p. 23-33.
  5. SCHWARTZ, CL., et al. QT interval prolongation in anthracycline-treated survivors of childhood cancer. J. Clin. Oncol., 1993, vol. 11, p. 1906-1910. Go to original source... Go to PubMed...
  6. SARRUBI, B., et al. Ventricular repolarization indexes following anthracycline treatment. Heart Vessels, 1997, vol. 12, p. 262-266. Go to original source... Go to PubMed...
  7. HORÁČEK, JM. - PUDIL, R. - JEBAVÝ, L., et al. Elektrokardiografické změny v souvislosti s léčbou antracykliny u akutních leukemií. Lék. Zprávy, 2006, roč. 51, s. 225-231.
  8. LARSEN, RL., et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am. J. Cardiol., 1992, vol. 70, p. 73-77. Go to original source... Go to PubMed...
  9. OKUMA, K. - ARIYOSHI, Y. - OTA, K. Clinical study of acute cardiotoxicity of anti-cancer agents-analysis using Holter ECG monitoring. Gan To Kagaku Ryoho, 1988, vol. 15, p. 893-900.
  10. VIGLIONE, PN. - PRAPROTNIK, A. - PINTO, JE. In vitro evaluation of acute effects of mitoxantrone (Novantrone) in rat and guinea pig atria. Pharmacol. Toxicol., 1993, vol. 72, p. 208-212. Go to original source... Go to PubMed...
  11. YOUSSEF, G. - LINKS, M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am. J. Cardiovasc. Drugs, 2005, vol. 5, p. 233-243. Go to original source... Go to PubMed...
  12. ELBL, L. Poškození kardiovaskulárního aparátu při léčbě onkologických onemocnění. Vnitř. Lék., 2002, roč. 48, s. 619-625.
  13. IWATA, N., et al. Aclarubicin-associated QTc prolongation and ventricular fibrillation. Cancer Treat. Rep., 1984, vol. 68, p. 527-529. Go to PubMed...
  14. KISHI, S., et al. Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia. Int. J. Hematol., 2000, vol. 71, p. 172-179. Go to PubMed...
  15. SKADBERG, BT., et al. Sudden death caused by heart block in a patient with multiple myeloma and cardiac amyloidosis. Acta Med. Scand., 1988, vol. 223, p. 379-383. Go to original source... Go to PubMed...
  16. BILLINGHAM, ME. - MASEK, MA. The pathology of anthracycline cardiotoxicity in children, adolescents and adults. In BRICKER, JT., et al. Cardiac toxicity after treatment for childhood cancer. New York, Wiley-Liss, 1993, p. 17-24.
  17. KLENER, P. Protinádorová terapie. 1. vyd. Praha, Galén 1996. 614 s.
  18. GERSL, V. - BAJGAR, J, - KRS, O., et al. Changes in cholinesterase activities after daunorubicin administration to rabbits. Hum. Exp. Toxicol., 1996, vol. 15, p. 834-838. Go to original source... Go to PubMed...
  19. GERSL, V. - BAJGAR, J. - HRDINA, R., et al. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits. Gen. Physiol. Biophys. 1999, vol. 18, p. 335-346. Go to PubMed...
  20. LOWN, B. - WOLF, M. Approaches to sudden death from coronary hearth disease. Circulation, 1971, vol. 44, p. 130-142. Go to original source... Go to PubMed...
  21. SURAWICZ, B. R on T phenomenon: dangerous and harmless. J. Appl. Cardiol., 1986, vol. 1, p. 39-61.
  22. BRILL, DM. - MAISEL, AS. - PRABHU, R. Polymorphic ventricular tachycardia and other complex arrhythmias in organophosphate insecticide poisoning. J. Electrocardiol., 1984, vol. 17, p. 97-102. Go to original source... Go to PubMed...
  23. BAYDIN, A., et al. Is there a relationship between the blood cholinesterase and QTc interval in the patients with acute organophosphate poisoning? Int. J. Clin. Pract., 2007, vol. 61, p. 927-30. Go to original source... Go to PubMed...
  24. JANG, SW. - LIN, JL. - CHUANG, FR. Electrocardiographic findings of organophosphate intoxication in emergency department as predictors of prognosis: a retrospective analysis. Changgeng Yi Xue Za Zhi, 1995 Jun, vol. 18, no. 2, p. 120-125. Go to PubMed...
  25. RAVINGEROVÁ, T., et al. Free oxygen radicals contribute to high incidence of reperfusion-induced arrhythmias in isolated rat heart. Life Sci., 1999, vol. 65, p. 1927-1930. Go to original source... Go to PubMed...